Earnings Call Summary | AxoGen(AXGN.US) Q1 2024 Earnings Conference
Earnings Call Summary | AxoGen(AXGN.US) Q1 2024 Earnings Conference
The following is a summary of the AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript:
以下是AxoGen公司（AXGN）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
AxoGen reported a Q1 revenue increase of 12.9% to $41.4 million compared to last year.
Gross profit for the quarter was $32.6 million, an increase from $28.5 million recorded last year.
This represents a gross margin of 78.8%, up from 77.7% last year.
The net loss for the quarter was $6.6 million.
AxoGen報告稱，與去年相比，第一季度收入增長了12.9％，達到4,140萬美元。
該季度的毛利爲3,260萬美元，較去年的2850萬美元有所增加。
這意味着毛利率爲78.8％，高於去年的77.7％。
該季度的淨虧損爲660萬美元。
Business Progress:
業務進展：
AxoGen plans to submit a Biologics License Application (BLA) for Avance nerve graft by Q3 2024, with potential approval in mid 2025.
The company introduced new products to the protection space and Resensation technique for implant-based breast neurotization.
Continued expansion of nerve protection offerings with Avive+ Soft Tissue Matrix is underway.
AxoGen is driving sales productivity and penetrating high potential accounts across multiple surgeon specialties.
Increasing demand and interest in AxoGen's Resensation technique and growth in breast neurotization have been observed.
The company has begun to see migration of procedures into ambulatory surgery centers due to improved reimbursement structures.
AxoGen計劃在2024年第三季度之前提交Avance神經移植的生物製劑許可申請（BLA），並可能在2025年中期獲得批准。
該公司爲保護空間推出了新產品和用於基於植入物的乳房神經化的Resensation技術。
Avive+ 軟組織矩陣的神經保護產品正在持續擴展中。
AxoGen正在提高銷售效率，並滲透到多個外科醫生專業領域的高潛力客戶。
已經觀察到對AxoGen的Resensation技術的需求和興趣不斷增加，乳房神經化也在增長。
由於報銷結構的改善，該公司已開始將手術轉移到門診手術中心。
More details: AxoGen IR
更多詳情： axoGen IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。